Hepatitis B immune globulin in liver transplantation prophylaxis: an update

Payam Dindoost, Seyed Mohammad Jazayeri, Seyed Moayed Alavian, Payam Dindoost, Seyed Mohammad Jazayeri, Seyed Moayed Alavian

Abstract

Context: Liver transplantation is the best treatment option for end-stage liver disease following hepatitis B (HBV) infection. However, the high rate of recurrence of HBV infection following transplantation is a disadvantage of this option.

Evidence acquisition: Over the past 2 decades, the gold standard of prophylactic treatment for the prevention of HBV re-infection following liver transplantation has been the administration of low- to high-dose hepatitis B immune globulin (HBIg) along with an antiviral agent to induce passive immunity.

Results: The effectiveness of HBIg in preventing the recurrence of HBV depends on the dosage, route of administration, and duration of HBIg treatment, and the viremic status at the time of transplantation. There is currently no consensus on a standardized recommendation for therapeutic options that include HBIg administration.

Conclusion: This review attempts to summarize the available data on the feasibility of such options. Most recent studies support the use of long-term combination therapy of HBIg and antiviral NAs (especially new agents).

Keywords: Hepatitis B Hyperimmune Globulin; Liver Transplantation; Prevention and Control.

References

    1. Alliance WH. Viral Hepatitis. Global Policy. 2010 Available From
    1. Yan ML, Yan LN, Li B, Zeng Y, Wen TF, Wang WT, Yang JY, Xu MQ, Li ZH, Chen YB. Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int. 2006;5(3):360–3.
    1. Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int. 2002;1(3):327–9.
    1. Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010;16(7):885–94. doi: 10.1002/lt.22084.
    1. Roque-Afonso AM, Feray C, Samuel D, Simoneau D, Roche B, Emile JF, Gigou M, Shouval D, Dussaix E. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors. Gut. 2002;50(1):95–9. doi: 10.1136/gut.50.1.95.
    1. Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y, Zhang M. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006;12(2):253–8. doi: 10.1002/lt.20701.
    1. Yen RD, Bonatti H, Mendez J, Aranda-Michel J, Satyanarayana R, Dickson RC. Case report of lamivudine-resistant hepatitis B virus infection post liver transplantation from a hepatitis B core antibody donor. Am J Transplant. 2006;6(5 Pt 1):1077–83. doi: 10.1111/j.1600-6143.2006.01313.x.
    1. Coffin CS, Terrault NA. Management of hepatitis B in liver transplant recipients. J Viral Hepat. 2007;14 (Suppl 1):37–44. doi: 10.1111/j.1365-2893.2007.00916.x.
    1. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: a European and an American perspective. Liver Transpl. 2005;11(7):716–32. doi: 10.1002/lt.20492.
    1. Mehrabi A, Esmaeilzadeh M, Fonouni H, Hafezi M, Rahbari NN, Golriz M, Majlesara A, Rad MT, Sadeghi M, Schmidt J, Ganten TM. The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation. Langenbecks Arch Surg. 2011
    1. Lok ASF. Liver transplantation for chronic hepatitis B virus infection. 2011 Available From: .
    1. Engler SH, Sauer PW, Golling M, Klar EA, Benz C, Stremmel W, Kallinowski B. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates. Eur J Gastroenterol Hepatol. 2001;13(4):363–7. doi: 10.1097/00042737-200104000-00010.
    1. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology. 1995;22(1):36–43.
    1. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H, Baquerizo A, Geevarghese S, Han SH, Goldstein L, Holt CD, Gornbein JA, Busuttil RW. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 2002;235(5):611–9; discussion 9-20. doi: 10.1097/00000658-200205000-00002.
    1. Marzano A, Gaia S, Ghisetti V, Carenzi S, Premoli A, Debernardi-Venon W, Alessandria C, Franchello A, Salizzoni M, Rizzetto M. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11(4):402–9. doi: 10.1002/lt.20402.
    1. Saab S, Waterman B, Chi AC, Tong MJ. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl. 2010;16(3):300–7.
    1. Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci. 2005;2(1):41–9. doi: 10.7150/ijms.2.41.
    1. Van Thiel DH, Schade RR, Gavaler JS, Shaw BW, Jr., Iwatsuki S, Starzl TE. Medical aspects of liver transplantation. Hepatology. 1984;4(1 Suppl):79S–83S. doi: 10.1002/hep.1840040721.
    1. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6(6):741–8. doi: 10.1053/jlts.2000.18702 .
    1. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;329(25):1842–7. doi: 10.1056/NEJM199312163292503.
    1. Shafique U, Watson C. Current and Evolving Prophylactic Strategies Against Hepatitis B Virus Re-infection Following Liver Transplantation. Euro Gastroenterol Hepatol Rev. 2010;6(1):78–81.
    1. Riediger C, Berberat PO, Sauer P, Gotthardt D, Weiss KH, Mehrabi A, Merle U, Stremmel W, Encke J. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Nephrol Dial Transplant. 2007;22(Suppl 8):viii37–viii46.
    1. Wang ZF, Liu C. Liver retransplantation: indications and outcomes. Hepatobiliary Pancreat Dis Int. 2004;3(2):175–8.
    1. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med. 2003;253(5):544–52. doi: 10.1046/j.1365-2796.2003.01134.x.
    1. Neff GW, O'Brien C B, Nery J, Shire N, Montalbano M, Ruiz P, Nery C, Safdar K, De Medina M, Tzakis AG, Schiff ER, Madariaga J. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl. 2004;10(11):1372–8. doi: 10.1002/lt.20277.
    1. Nery JR, Nery-Avila C, Reddy KR, Cirocco R, Weppler D, Levi DM, Nishida S, Madariaga J, Kato T, Ruiz P, Schiff E, Tzakis AG. Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine. Transplantation. 2003;75(8):1179–86. doi: 10.1097/01.TP.0000065283.98275.FE.
    1. van Nunen AB, de Man RA, Heijtink RA, Vossen AC, Schalm SW. Passive immunization of chronic hepatitis B patients on lamivudine therapy: a feasible issue? J Viral Hepat. 2002;9(3):221–8. doi: 10.1046/j.1365-2893.2002.00337.x.
    1. Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, Magalini S, Agnes S, Castagneto M. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc. 2008;40(6):1961–4. doi: 10.1016/j.transproceed.2008.05.071.
    1. Dickson RC, Terrault NA, Ishitani M, Reddy KR, Sheiner P, Luketic V, Soldevila-Pico C, Fried M, Jensen D, Brown RS Jr, Horwith G, Brundage R, Lok A. Protective antibody levels and dose requirements for IV 5% Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease. Liver Transpl. 2006;12(1):124–33. doi: 10.1002/lt.20582.
    1. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003;3(8):999–1002. doi: 10.1034/j.1600-6143.2003.00191.x.
    1. Germer JJ, Charlton MR, Ishitani MB, Forehand CD, Patel R. Characterization of hepatitis B virus surface antigen and polymerase mutations in liver transplant recipients pre- and post-transplant. Am J Transplant. 2003;3(6):743–53. doi: 10.1034/j.1600-6143.2003.00149.x.
    1. Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park JI, Ryu JH, Lee HJ, Suh DJ, Lim YS. Prevention of hepatitis B recurrence after living donor liver transplantation: primary high-dose hepatitis B immunoglobulin monotherapy and rescue antiviral therapy. Liver Transpl. 2008;14(6):770–8. doi: 10.1002/lt.21440.
    1. Iacob S, Hrehoret D, Matei E, Dorobantu B, Gangone E, Gheorghe L, Popescu I. Costs and efficacy of “on demand” low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation. J Gastrointestin Liver Dis. 2008;17(4):383–8.
    1. Kwon CH, Suh KS, Cho JY, Yi NJ, Jang JJ, Lee KU. Change of hepatitis B virus DNA status in anti-HBc positive liver graft. Korean J Hepatol. 2006;12(2):191–200.
    1. Lee KW, Lee DS, Lee HH, Kim SJ, Joh JW, Seo JM, Choe YH, Lee SK. Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation. Transplant Proc. 2004;36(8):2311–2. doi: 10.1016/j.transproceed.2004.08.139.
    1. Manzarbeitia C, Reich DJ, Ortiz JA, Rothstein KD, Araya VR, Munoz SJ. Safe use of livers from donors with positive hepatitis B core antibody. Liver Transpl. 2002;8(6):556–61. doi: 10.1053/jlts.2002.33451.
    1. Steinmuller T, Seehofer D, Rayes N, Muller AR, Settmacher U, Jonas S, Neuhaus R, Berg T, Hopf U, Neuhaus P. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002;35(6):1528–35. doi: 10.1053/jhep.2002.33681.
    1. Campos-Varela I, Castells L, Buti M, Vargas V, Bilbao I, Rodriguez-Frias F, Jardí R, Charco R, Guardia J, Esteban R. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Ann Hepatol. 2011;10(2):180–7.
    1. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol. 2007;22(12):2130–4. doi: 10.1111/j.1440-1746.2006.04609.x.
    1. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl. 2000;6(4):429–33. doi: 10.1053/jlts.2000.8310.
    1. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology. 2008;48(5):1460–6. doi: 10.1002/hep.22524.
    1. Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey GP, McCaughan GW, Australasian Liver Transplant Study Group. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology. 2007;132(3):931–7. doi: 10.1053/j.gastro.2007.01.005.
    1. Takaki A, Yagi T, Iwasaki Y, Sadamori H, Matsukawa H, Matsuda H, Shinoura S, Umeda Y, Miyake Y, Terada R, Kobashi H, Sakaguchi K, Tanaka N, Shiratori Y. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation. 2007;83(2):231–3. doi: 10.1097/01.tp.0000246310.75638.86.
    1. Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, Yang JM, Choi SW, Han NI, Kim DG. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol. 2008;80(11):1891–9. doi: 10.1002/jmv.21324.
    1. Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int. 2008;7(4):357–61.
    1. Suehiro T, Shimada M, Kishikawa K, Shimura T, Soejima Y, Yoshizumi T, Hashimoto K, Mochida Y, Maehara Y, Kuwano H. Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation. Liver Int. 2005;25(6):1169–74. doi: 10.1111/j.1478-3231.2005.01165.x.
    1. Targhetta S, Villamil F, Inturri P, Pontisso P, Fagiuoli S, Cillo U, Cecchetto A, Gianni S, Naccarato R, Burra P. Protocol liver biopsies in long-term management of patients transplanted for hepatitis B-related liver disease. World J Gastroenterol. 2006;12(11):1706–12.
    1. Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant. 2006;6(11):2680–5. doi: 10.1111/j.1600-6143.2006.01542.x.
    1. Wang ZX, Ding GS, Fu H, Zhang JJ, Chen XS, Guo WY, Shi XM, Fu ZR. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int. 2004;3(3):345–8.
    1. Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int. 2011:[Epub ahead of print].
    1. Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, Maluf D, Coterell A, Posner MP, Fisher RA. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int. 2008;28(1):72–8. doi: 10.1111/j.1478-3231.2007.01611.x.
    1. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, Kizilisik AT, Bagous T, Trofe J, Stratta RJ, Egidi MF, Gaber AO. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis. 2002;4(3):137–43. doi: 10.1034/j.1399-3062.2002.01012.x.
    1. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology. 2000;32(6):1189–95. doi: 10.1053/jhep.2000.19789.
    1. Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, Klempnauer J, Tillmann HL, Manns MP, Rosenau J. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl. 2008;14(4):435–42. doi: 10.1002/lt.21343.
    1. Powell JJ, Apiratpracha W, Partovi N, Erb SR, Scudamore CH, Steinbrecher UP, Buczkowski AK, Chung SW, Yoshida EM. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant. 2006;20(4):524–5. doi: 10.1111/j.1399-0012.2006.00517.x.
    1. Singham J, Greanya ED, Lau K, Erb SR, Partovi N, Yoshida EM. Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol. 2010;9(2):166–71.
    1. McGory RW, Ishitani MB, Oliveira WM, Stevenson WC, McCullough CS, Dickson RC, Caldwell SH, Pruett TL. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation. 1996;61(9):1358–64. doi: 10.1097/00007890-199605150-00013.
    1. Terrault NA, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology. 1996;24(6):1327–33. doi: 10.1002/hep.510240601.
    1. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, Gentilcore E, Piantino P, Barbui AM, David E, Negro F, Rizzetto M. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34(6):903–10. doi: 10.1016/S0168-8278(01)00080-0.
    1. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28(2):585–9. doi: 10.1002/hep.510280241.
    1. Protzer-Knolle U, Naumann U, Bartenschlager R, Berg T, Hopf U, Meyer zum Buschenfelde KH, Neuhaus P, Gerken G. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology. 1998;27(1):254–63. doi: 10.1002/hep.510270138.
    1. Gow PJ, Mutimer D. Mechanisms of hepatitis B virus escape after immunoglobulin therapy. Curr Opin Infect Dis. 2000;13(6):643–6. doi: 10.1097/00001432-200012000-00011.
    1. Wong SN, Chu CJ, Wai CT, Howell T, Moore C, Fontana RJ, Lok AS. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl. 2007;13(3):374–81. doi: 10.1002/lt.21041.
    1. Degertekin B, Han SH, Keeffe EB, Schiff ER, Luketic VA, Brown RS, Jr., Emre S, Soldevila-Pico C, Reddy KR, Ishitani MB, Tran TT, Pruett TL, Lok AS, NIH HBV-OLT Study Group. Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation. Am J Transplant. 2010;10(8):1823–33. doi: 10.1111/j.1600-6143.2010.03046.x.
    1. Deeney HN, Dusheiko GM. Lamivudine combined with hepatitis B immunoglobulin in for prophylaxis of hepatitis B recurrence after liver transplantation: time for a change? Transpl Int. 2009;22(4):385–6. doi: 10.1111/j.1432-2277.2009.00837.x.
    1. Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int. 2011;5(2):635–43. doi: 10.1007/s12072-010-9250-y.
    1. Donataccio D, Roggen F, De Reyck C, Verbaandert C, Bodeus M, Lerut J. Use of anti-HBc positive allografts in adult liver transplantation: toward a safer way to expand the donor pool. Transpl Int. 2006;19(1):38–43. doi: 10.1111/j.1432-2277.2005.00225.x.
    1. Muller R, Samuel D, Fassati LR, Benhamou JP, Bismuth H, Alexander GJ. 'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis. J Hepatol. 1994;21(6):1140–3. doi: 10.1016/S0168-8278(05)80632-4.
    1. Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol. 2009;15(20):2489–99. doi: 10.3748/wjg.15.2489.
    1. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant. 2003;3(3):250–8. doi: 10.1034/j.1600-6143.2003.00063.x.
    1. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis. 2004;24(Suppl 1):55–62. doi: 10.1055/s-2004-828679.
    1. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, Saab S, Durazo F, Goldstein L, Farmer D, Ghobrial RM, Busuttil RW. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation. Liver Transpl. 2003;9(2):182–7. doi: 10.1053/jlts.2003.50002.
    1. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, Herrero JI, Jardí R, Cruz de Castro E, García-Rey C. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol. 2003;38(6):811–7. doi: 10.1016/S0168-8278(03)00087-4.
    1. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation. 2004;77(8):1203–8. doi: 10.1097/01.TP.0000118904.63669.EB.
    1. Ferretti G, Merli M, Ginanni Corradini S, Callejon V, Tanzilli P, Masini A, Ferretti S, Iappelli M, Rossi M, Rivanera D, Lilli D, Mancini C, Attili A, Berloco P. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc. 2004;36(3):535–8. doi: 10.1016/j.transproceed.2004.02.025.
    1. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, Böker KHW. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001;34(6):895–902. doi: 10.1016/S0168-8278(01)00089-7.
    1. Terrault NA, Zhou S, McCory RW, Pruett TL, Lake JR, Roberts JP, Ascher NL, Wright TL. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology. 1998;28(2):555–61. doi: 10.1002/hep.510280237.
    1. Tillmann HL, Trautwein C, Bock T, Boker KH, Jackel E, Glowienka M, Oldhafer K, Bruns I, Gauthier J, Condreay LD, Raab HR, Manns MP. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology. 1999;30(1):244–56. doi: 10.1002/hep.510300141.
    1. Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int. 2010;4(4):707–15. doi: 10.1007/s12072-010-9188-0.
    1. Jimenez-Perez M, Saez-Gomez AB, Mongil Poce L, Lozano-Rey JM, de la Cruz-Lombardo J, Rodrigo-Lopez JM. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc. 2010;42(8):3167–8. doi: 10.1016/j.transproceed.2010.05.127.
    1. Genzini T, Dos Santos RG, Pedrosa C, Curvelo LA, Noujaim HM, Crescentini F, Mota LT, Guirro TG, Ferreira FY, Salomão P, Pereira JR, de Miranda MP. Liver transplantation in bearers of hepatitis B associated or not with delta hepatitis in the age of the new antiviral drugs: is hyperimmune globulin still necessary? Transplant Proc. 2010;42(2):496–7. doi: 10.1016/j.transproceed.2010.01.008.
    1. Xi ZF, Xia Q, Zhang JJ, Chen XS, Han LZ, Wang X. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis. 2009;10(4):321–7. doi: 10.1111/j.1751-2980.2009.00403.x.
    1. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir Monotherapy is Eeffective in Suppressing Hepatitis B Virus after Liver Transplantation. Gastroenterology. 2011;141(4):1212–9. doi: 10.1053/j.gastro.2011.06.083.
    1. Loomba R, Rowley AK, Wesley R, Smith KG, Liang TJ, Pucino F, Csako G. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol. 2008;6(6):696–700. doi: 10.1016/j.cgh.2008.02.055.
    1. Alonso I, Herreros de Tejada A, Moreno JM, Rubio E, Lucena JL, De la Revilla J. Effectiveness of low-dose intramuscular anti-VHB immune globulin in the prophylaxis of viral B hepatitis reinfection after liver transplantation: preliminary report. Transplant Proc. 2003;35(5):1850–1. doi: 10.1016/S0041-1345(03)00634-1.
    1. Dodson SF, de Vera ME, Bonham CA, Geller DA, Rakela J, Fung JJ. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl. 2000;6(4):434–9. doi: 10.1053/jlts.2000.6446.
    1. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant. 2003;17(3):254–8. doi: 10.1034/j.1399-0012.2003.00044.x.
    1. Filipponi F, Franchello A, Carrai P, Romagnoli R, De Simone P, Woodward MK. Efficacy, safety, and pharmacokinetics of intramuscular hepatitis B immune globulin, Igantibe, for the prophylaxis of viral B hepatitis after liver transplantation. Dig Liver Dis. 2010;42(7):509–14. doi: 10.1016/j.dld.2009.09.005.
    1. Jiao ZY, Yan LN, Li B, Zeng Y, Wen TF, Lu SC, Zhao JC, Wang WT, Xu MQ, Yang JY, Li ZH, Ma YK, Zhang ZW, Chen ZY. [Liver transplantation for chronic hepatitis B patients with lamivudine monotherapy or lamivudine combined with individualized low-dose hepatitis B immunoglobulin treatment] Zhonghua Gan Zang Bing Za Zhi. 2007;15(11):804–8.
    1. Karademir S, Astarcioglu H, Akarsu M, Ozkardesler S, Ozzeybek D, Sayiner A, Akan M, Tankurt E, Astarcioğlu I. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc. 2006;38(2):579–83. doi: 10.1016/j.transproceed.2005.12.063.
    1. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation. 2010;90(7):786–90. doi: 10.1097/TP.0b013e3181f09c89.
    1. Yang Y, Zhang Q, Cai CJ, Lu MQ, Li X, Jiang N, Jiang H, Xu C, Li H, Wang GS, Yi SH, Zhang J, Zhang JF, Yi HM, Zhang YC, Chen GH. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant. Chin Med J (Engl) 2007;120(16):1400–3.
    1. Chun J, Kim W, Kim BG, Lee KL, Suh KS, Yi NJ, Park KU, Kim YJ, Yoon JH, Lee HS. High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence. Am J Transplant. 2010;10(7):1649–59. doi: 10.1111/j.1600-6143.2010.03162.x.
    1. Freshwater DA, Dudley T, Cane P, Mutimer DJ. Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study. Transplantation. 2008;85(8):1105–11. doi: 10.1097/TP.0b013e31816a342a.
    1. Lee SK, Park JH, Joh JW, Kim SJ, Choi IS, Choi SH, Heo JS, Lee WY, Sohn TS, Kim YI, Paik SW, Koh KC, Lee JH, Kim SM, Peck KR, Song JH, Lee BB. Prophylaxis against hepatitis B recurrence following liver transplantation in HBs Ag(+) patients. Transplant Proc. 2000;32(7):2248–9. doi: 10.1016/S0041-1345(00)01786-3.
    1. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant. 2007;21(4):510–7. doi: 10.1111/j.1399-0012.2007.00678.x.
    1. Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, Lee SK, Kim SI, Lee KU. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2007;13(3):451–8. doi: 10.1002/lt.21043.
    1. Yoshida H, Kato T, Levi DM, Regev A, Madariaga JR, Nishida S, Martinez EJ, Schiff ER, Omata M, Tzakis AG. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant. 2007;21(2):166–71. doi: 10.1111/j.1399-0012.2006.00557.x .

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere